Talk to the Veterans Crisis Line now
U.S. flag
An official website of the United States government

Health Services Research & Development

Go to the ORD website
Go to the QUERI website

HSR&D Citation Abstract

Search | Search by Center | Search by Source | Keywords in Title

Higher symptom burden is associated with lower function in women taking adjuvant endocrine therapy for breast cancer.

Sitlinger A, Shelby RA, Van Denburg AN, White H, Edmond SN, Marcom PK, Bosworth HB, Keefe FJ, Kimmick GG. Higher symptom burden is associated with lower function in women taking adjuvant endocrine therapy for breast cancer. Journal of geriatric oncology. 2019 Mar 1; 10(2):317-321.

Related HSR&D Project(s)

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.
   Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions



Abstract:

OBJECTIVE: To explore the impact of symptoms on physical function in women on adjuvant endocrine therapy for breast cancer. METHODS: Eligible women were postmenopausal, had hormone receptor positive, stage I-IIIA breast cancer, completed surgery, chemotherapy, radiation, and on adjuvant endocrine therapy. At a routine follow-up visit, women (N? = 107) completed standardized symptom measures: Brief Fatigue Inventory, Brief Pain Inventory, Menopause Specific Quality of Life Questionnaire, Functional Assessment of Cancer Therapy Neurotoxicity scales. Two performance measures assessed function: grip strength (Jamar dynamometer; n? = 71) and timed get-up-and-go (TUG; n? = 103). Analyses were performed with an overall symptom composite score. Correlations and multiple linear regression analyses were performed to test adverse effects on physical function. RESULTS: The mean age was 64?years (range 45-84), 81% white, 84% on an aromatase inhibitor, and on endocrine therapy for mean 35?months (range 1-130?months). Dominant hand grip strength was inversely correlated with symptom composite scores (r? = -0.29, p? = .02). Slower TUG was positively correlated with higher Charlson comorbidity level (r? = 0.36, p? < .001) and higher symptom composite scores (r? = 0.24, p? = .01). In multivariate analyses, weaker dominant and non-dominant hand grip strength were significantly associated with greater symptom composite scores (ß? = -0.27, t? = 2.43, p? = .02 and ß? = -0.36, t? = 3.15, p? = .003, respectively) and slower TUG was associated with higher symptom composite scores (ß? = 0.18, t? = 1.97, p? = .05). CONCLUSIONS: Higher symptom burden is associated with worse physical function, as measured by hand grip strength and TUG. Further study to determine the impact of endocrine therapy and its side effects on function is warranted.





Questions about the HSR&D website? Email the Web Team.

Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.